#NewAseBioMember | " AseBio represents a space that raises the collective bar: being a member means contributing and staying accountable"

AseBio. What does your company's work bring to the table and what is its strength?

Pedro Gonzáles Sánchez. At BePharma Institute, we drive the professionalization and growth of the pharmaceutical and biotech sectors through specialized training that is practical and aligned with real market needs.

Our main strength lies in turning knowledge into actionable skills: less theory that sits in a drawer and more useful tools that help accelerate projects, improve processes, and develop talent prepared for today’s challenges.

Another key aspect is our ability to connect industry, innovation, and training—acting as a bridge that equips companies with better-prepared professionals and gives professionals a more strategic perspective.

AseBio. What is AseBio for you?

Pedro Gonzáles Sánchez. AseBio is an essential meeting point that brings together the voice of the biotech sector in Spain. For us, it is a platform that unifies interests, boosts industry visibility, and facilitates collaborations that would otherwise be difficult to create.

It also represents a space that raises the collective bar: being a member means contributing and staying accountable.

AseBio. When did you first hear about AseBio?

Pedro Gonzáles Sánchez. Several years ago, AseBio has long been a reference whenever biotech innovation and development in Spain were discussed.

AseBio. What do you expect from being part of an association like AseBio?

Pedro Gonzáles Sánchez. We xpect real, two-way collaboration: to contribute, but also to learn. We are especially interested in participating in initiatives that strengthen training, knowledge transfer, and talent development in the biotech field. We also aim to build strategic alliances and help the sector gain greater visibility both nationally and internationally.

And to be practical: we want to be where decisions are made, where trends are detected, and where opportunities emerge.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Pedro Gonzáles Sánchez. Across the biotech sector, one of the major challenges is speed: science moves fast, but regulatory structures, funding models, and talent development often struggle to keep pace.

For us, the challenge is anticipating those needs and designing training that doesn’t lag behind market expectations but stays ahead of them. It is also crucial to help talent understand the sector in all its complexity—from innovation and regulation to business, communication, and technology transfer.